Novonesis: 7% organic sales growth in 9M and 2026 outlook confirmed
FROM THE WIRE · FINANCE.YAHOO.COM
Novonesis (Novozymes A/S) COPENHAGEN, Denmark – November 5, 2026. Novonesis delivered strong Q3 sales leading to 9M financial results at 7% organic sales growth and adjusted EBITDA margin of 37.9%. In addition, our 2026 outlook is confirmed at 7-8% organic sales growth with an…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishResults in line with expectations and outlook confirmed, with EBITDA margin toward the high end of guidance.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 019M organic sales growth was 7%, with Q3 at 6%.
- 02Adjusted EBITDA margin was 37.9%.
- 03The 2026 outlook is confirmed at 7-8% organic sales growth.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets